How do 5-HT3 antagonists compare to dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting?

For highly emetogenic chemotherapy (HEC), preventing nausea and vomiting is critical. 5-HT3 antagonists (like palonosetron) and dexamethasone are both standard antiemetics, but they work differently. Research shows that combining a 5-HT3 antagonist with dexamethasone is more effective than either alone, and current guidelines recommend using them together as part of a multi-drug regimen that also includes an NK1 receptor antagonist and often olanzapine.

What the research says

A 2020 network meta-analysis found that adding olanzapine to palonosetron plus dexamethasone significantly improved complete response (no vomiting and no rescue medication) in the acute, delayed, and overall phases compared to palonosetron plus dexamethasone alone ⁹. This suggests that the two-drug combination of a 5-HT3 antagonist and dexamethasone is effective, but adding other agents can further improve outcomes. A 2022 cost-effectiveness analysis from a US payer perspective compared four regimens: palonosetron plus dexamethasone (two-drug), adding an NK1 receptor antagonist (three-drug), adding olanzapine (three-drug), and all four drugs together (four-drug). The four-drug regimen (palonosetron + NK1-RA + dexamethasone + olanzapine) provided the highest rates of complete response and absence of nausea, though at higher costs ¹¹. A 2023 systematic review and meta-analysis from the Japan Society of Clinical Oncology confirmed that adding olanzapine to a triplet of 5-HT3 antagonist, NK1 receptor antagonist, and dexamethasone significantly improved control of nausea and vomiting, especially in the delayed phase, with low rates of serious side effects like hyperglycemia and somnolence ¹⁰. Overall, the evidence supports that 5-HT3 antagonists and dexamethasone are foundational, but for HEC, they should be used together with an NK1 receptor antagonist and often olanzapine for optimal protection.

What to ask your doctor

• What antiemetic regimen do you recommend for my chemotherapy, and does it include a 5-HT3 antagonist, dexamethasone, and an NK1 receptor antagonist?
• Would adding olanzapine to my antiemetic regimen be appropriate given my specific chemotherapy and health profile?
• What are the potential side effects of each antiemetic, especially dexamethasone (e.g., insomnia, hyperglycemia) and olanzapine (e.g., drowsiness)?
• How should I take these medications—before, during, or after chemotherapy—and for how long?
• Are there any interactions between these antiemetics and my other medications or medical conditions?